BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $106.12 -1.39%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
BMO Capital upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Outperform with a price target of $12.00 (from $4.00).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $7.21 yesterday.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $7.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
- Argus Upgrades APA Corp. (APA) to Buy
- Northland Upgrades CIENA (CIEN) to Outperform
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
